cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4596374
title: Reanalysis of Reynolds 2021 dataset

description: In this repo, we upload the AnnData files necessary for the analysis of Reynolds et al. (2021) dataset. Additionally, we include the Jupyter notebook files used during the analysis, with the cells run to see the results.
DOI: 10.5281/zenodo.5996900
title: Dataset related to article "Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors"

description: This record contains raw data related to article “Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors" <strong>Introduction: </strong> In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). <strong>Methods: </strong> Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response assessment after 6-8 weeks. Patients who received ATB within 1 month before or after the first dose of ICI were compared with those who did not. Response assessment according to iRECIST and EORTC was evaluated, as well as progression-free survival (PFS) and overall survival (OS). For semi-quantitative parameters, we computed metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their variations (∆). <strong>Results: </strong> Twenty NSCLC cases of 50 (40%) had received ATB. Patients receiving ATB had a higher number of metastases (<em>p</em> = 0.046), and were associated with an elevated tumor burden, expressed by TLG (687 vs. 235.3, <em>p</em> = 0.007) and MTV (125.6 vs. 40.6, <em>p</em> = 0.002), compared to no-ATB patients. According to iRECIST, progressive disease rate was significantly higher for ATB group (64.7% vs. 27.6%, <em>p</em> = 0.029). Likewise, PFS was shorter for ATB compared to no-ATB (median 4.1 vs. 12.4 months, <em>p</em> = 0.004), while no difference for OS was detected. On multivariate analysis, the effect of ATB remained significant for poor PFS along with performance status (ECOG ≥ 1), and ∆SUVmax. <strong>Conclusions: </strong> ATB therapy seems to be associated with a worse treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with ICI.
DOI: 10.5281/zenodo.5996899
title: Dataset related to article "Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors"

description: This record contains raw data related to article “Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors" <strong>Introduction: </strong> In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). <strong>Methods: </strong> Data from fifty NSCLC patients referred for ICI between December 2015 and May 2019 were analyzed. All patients underwent 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and contrast-enhanced CT at baseline and for response assessment after 6-8 weeks. Patients who received ATB within 1 month before or after the first dose of ICI were compared with those who did not. Response assessment according to iRECIST and EORTC was evaluated, as well as progression-free survival (PFS) and overall survival (OS). For semi-quantitative parameters, we computed metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their variations (∆). <strong>Results: </strong> Twenty NSCLC cases of 50 (40%) had received ATB. Patients receiving ATB had a higher number of metastases (<em>p</em> = 0.046), and were associated with an elevated tumor burden, expressed by TLG (687 vs. 235.3, <em>p</em> = 0.007) and MTV (125.6 vs. 40.6, <em>p</em> = 0.002), compared to no-ATB patients. According to iRECIST, progressive disease rate was significantly higher for ATB group (64.7% vs. 27.6%, <em>p</em> = 0.029). Likewise, PFS was shorter for ATB compared to no-ATB (median 4.1 vs. 12.4 months, <em>p</em> = 0.004), while no difference for OS was detected. On multivariate analysis, the effect of ATB remained significant for poor PFS along with performance status (ECOG ≥ 1), and ∆SUVmax. <strong>Conclusions: </strong> ATB therapy seems to be associated with a worse treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with ICI.
DOI: 10.5281/zenodo.5913188
title: samples inventory - single-stringer coupons for EoL research - ReINTEGRA

description: Open access to experimental data generated by the ReINTEGRA project (GA 886609, H2020, European Union, through Clean Sky 2 JU) along the research, at single-stringer coupon level, of the End-of-Life of novel welded Al-Li aerostructures. Research pertaining to Task 1.1 (WP1), Deliverable D1. Processed data originated from calliper and precision balance measurements conducted by AZTERLAN, to determine weight and dimensions of coupons supplied by ecoTECH partners. The file contains the physical description of samples from 15 references of coupons, being each reference a unique combination of stringer and skin alloys, welding technique, stringer configuration, coating and FSW sealant. The coupon samples have been used for investigating cutting strategies and decoating methods (WP2), remelting set-up (WP3) and pre-scrap characterisation protocols (WP4). The experimental plan, with estimation of number of samples required of each reference, was outlined as part of Task 1.1 (WP1).
DOI: 10.5281/zenodo.5913187
title: samples inventory - single-stringer coupons for EoL research - ReINTEGRA

description: Open access to experimental data generated by the ReINTEGRA project (GA 886609, H2020, European Union, through Clean Sky 2 JU) along the research, at single-stringer coupon level, of the End-of-Life of novel welded Al-Li aerostructures. Research pertaining to Task 1.1 (WP1), Deliverable D1. Processed data originated from calliper and precision balance measurements conducted by AZTERLAN, to determine weight and dimensions of coupons supplied by ecoTECH partners. The file contains the physical description of samples from 15 references of coupons, being each reference a unique combination of stringer and skin alloys, welding technique, stringer configuration, coating and FSW sealant. The coupon samples have been used for investigating cutting strategies and decoating methods (WP2), remelting set-up (WP3) and pre-scrap characterisation protocols (WP4). The experimental plan, with estimation of number of samples required of each reference, was outlined as part of Task 1.1 (WP1).
DOI: 10.25345/c5r57q
title: MassIVE MSV000088792 - Proteomics analysis of FFPE AIS thrombi
title: We analysed 31 formalin-fixed paraffin-embedded (FFPE) acute ischemic stroke thrombi of cardioembolic and atheroembolic etiology using a shotgun proteomic approach. Here we share the mass spec raw files of each sample to contribute to the investigation of thrombus proteome.
DOI: 10.6084/m9.figshare.12271292.v18
title: Arrival catalog of coronal mass ejections observed with STEREO Heliospheric Imagers (HELCATS ARRCAT 2.0)

description: ARRIVAL CATALOGUE 2.0 <br>In this ARRival CATalog (ARRCAT), the arrivals of solar coronal mass ejections that were tracked in the STEREO heliospheric imagers in the HELCATS project are calculated.<br>ARRCAT lists modeled arrivals of CMEs at various spacecraft and planets, between April 2007 - October 2021, based on the HIGeoCAT catalog of CMEs established at RAL Space, UK (R. A. Harrison, J. A. Davies, D. Barnes). <br>This is version 2.0, released 2020-May-13, updated 2021-Nov-25.<br>https://doi.org/10.6084/m9.figshare.12271292<br>It is based on this HIGeoCAT version: https://www.helcats-fp7.eu/catalogues/data/HCME_WP3_V06.vot using the SSEF30 model.<br>The catalog is available as python pandas dataframe (pickle), python numpy arrays (pickle, as recarray and structured array),npy (numpy, no pickle), json, csv, xlsx, txt, hdf5, html at https://helioforecast.space/arrcathttps://www.helcats-fp7.eu<br>Number of events in ARRCAT: 1699Targets: Earth_L1, STEREO-A, STEREO-B, Solar Orbiter, Parker Solar Probe (PSP), Bepi Colombo, Ulysses, Venus, Mercury, Mars.<br>For further description, see header file.<br>source code: arrcat.ipynb inhttps://github.com/cmoestl/heliocats<br>Rules: If results are produced with this catalog for peer-reviewed scientific publications,please contact christian.moestl@oeaw.ac.at for co-authorships.<br>
DOI: 10.5281/zenodo.5932916
title: Data for "Multiple Equilibria in Weak Temperature Gradient Simulations over a Moist Land-Like Surface"

description: Codes, simulation input files, and simulation output data supporting “Multiple Equilibria in Weak Temperature Gradient Simulations over a Moist Land-Like Surface”, submitted to GRL. README files in GRLWTGEquilibria.zip provide detailed descriptions of the archive contents.
DOI: 10.5281/zenodo.5932915
title: Data for "Multiple Equilibria in Weak Temperature Gradient Simulations over a Moist Land-Like Surface"

description: Codes, simulation input files, and simulation output data supporting “Multiple Equilibria in Weak Temperature Gradient Simulations over a Moist Land-Like Surface”, submitted to GRL. README files in GRLWTGEquilibria.zip provide detailed descriptions of the archive contents.
DOI: 10.1184/r1/12987959
title: The Index of Digital Humanities Conferences Data

description: While the term "Digital Humanities" dates back only to the early 2000s, the communities from which its current practitioners hail are quite a bit older. <i>The Index of Digital Humanities Conferences</i> is a collaboratively constructed dataset and website that presents conference metadata, and linked records within that data. You will find details about conference series and stand-alone academic events reaching back to the 1960s. In a subset, you will find works presented at these conferences: titles and authors, and occasionally additional information such as keywords, languages, and unformatted versions of abstracts or the full work text.<br>This deposit contains both the "full data" and "simple csv" downloads for the Index of Digital Humanities Conferences, as of 2022-02-04.<br>Further information on the data is available in the README as well as at https://dh-abstracts.library.cmu.edu/downloads<br>
DOI: 10.1184/r1/12987959.v3
title: The Index of Digital Humanities Conferences Data

description: While the term "Digital Humanities" dates back only to the early 2000s, the communities from which its current practitioners hail are quite a bit older. <i>The Index of Digital Humanities Conferences</i> is a collaboratively constructed dataset and website that presents conference metadata, and linked records within that data. You will find details about conference series and stand-alone academic events reaching back to the 1960s. In a subset, you will find works presented at these conferences: titles and authors, and occasionally additional information such as keywords, languages, and unformatted versions of abstracts or the full work text.<br>This deposit contains both the "full data" and "simple csv" downloads for the Index of Digital Humanities Conferences, as of 2021-09-17.<br>Further information on the data is available in the README as well as at https://dh-abstracts.library.cmu.edu/downloads<br>
DOI: 10.6084/m9.figshare.19131179
title: Na+.xlsx

description: The concentration of Ions around the Lake Urmia
DOI: 10.6084/m9.figshare.19131179.v2
title: Na+.xlsx

description: The concentration of Ions around the Lake Urmia
DOI: 10.6084/m9.figshare.19131179.v1
title: Na+.xlsx

description: The concentration of Ions around the Lake Urmia
DOI: 10.5281/zenodo.5997065
title: Dataset related to article "Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"

description: This record contains raw data related to article “Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience" <strong>Background: </strong> We analysed a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent extended Pleurectomy/Decortication (eP/D) in a centre with a high level of thoracic surgery experience (IRCCS Humanitas Research Hospital) to explore postoperative morbidity and mortality, pattern of recurrence and survival. <strong>Methods: </strong> A retrospective analysis was performed on MPM patients underwent eP/D in our centre from 2010 to 2021. All patients were identified from our departmental database. Postoperative complications were scored according to Clavien-Dindo criteria. Survival analysis was performed by the Kaplan-Meier methods and Cox multivariable analysis. <strong>Results: </strong> Eighty-five patients underwent extended pleurectomy decortication (eP/D) during study period. Macroscopical residual disease (R2) was reported in one case. A neoadjuvant chemotherapy regiment was administrated in 88% of the surgical cohort. A complete trimodality treatment including induction with platinum agents and pemetrexed, radical cytoreductive surgery and volumetric modulated arc therapy technology (VMAT) could be administered in 63 patients (74%). Postoperative morbidity rate was 54.11%, major complications (defined as Clavien-Dindo ≥ 3) were reported in 11 patients (12.9%). Thirty-day mortality and 90-day mortality were, respectively, 2.35% and 3.53%. Median disease-free and overall survival were, respectively, 13.7 and 25.5 months. The occurrence of major complications (Clavien-Dindo ≥ 3), operative time, pT3-T4, pathological node involvement (pN+) were prognostic factors associated with worse survival. <strong>Conclusions: </strong> In our experience, eP/D is a well-tolerated procedure with acceptable mortality and morbidity, allowing for the administration of trimodality regimens in most patients. eP/D offered in a multimodality treatment setting have satisfactory long term oncological results. To obtain best oncological results the goal of surgery should be macroscopic complete resection in carefully selected patients (clinical N0).
DOI: 10.5281/zenodo.5997064
title: Dataset related to article "Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"

description: This record contains raw data related to article “Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience" <strong>Background: </strong> We analysed a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent extended Pleurectomy/Decortication (eP/D) in a centre with a high level of thoracic surgery experience (IRCCS Humanitas Research Hospital) to explore postoperative morbidity and mortality, pattern of recurrence and survival. <strong>Methods: </strong> A retrospective analysis was performed on MPM patients underwent eP/D in our centre from 2010 to 2021. All patients were identified from our departmental database. Postoperative complications were scored according to Clavien-Dindo criteria. Survival analysis was performed by the Kaplan-Meier methods and Cox multivariable analysis. <strong>Results: </strong> Eighty-five patients underwent extended pleurectomy decortication (eP/D) during study period. Macroscopical residual disease (R2) was reported in one case. A neoadjuvant chemotherapy regiment was administrated in 88% of the surgical cohort. A complete trimodality treatment including induction with platinum agents and pemetrexed, radical cytoreductive surgery and volumetric modulated arc therapy technology (VMAT) could be administered in 63 patients (74%). Postoperative morbidity rate was 54.11%, major complications (defined as Clavien-Dindo ≥ 3) were reported in 11 patients (12.9%). Thirty-day mortality and 90-day mortality were, respectively, 2.35% and 3.53%. Median disease-free and overall survival were, respectively, 13.7 and 25.5 months. The occurrence of major complications (Clavien-Dindo ≥ 3), operative time, pT3-T4, pathological node involvement (pN+) were prognostic factors associated with worse survival. <strong>Conclusions: </strong> In our experience, eP/D is a well-tolerated procedure with acceptable mortality and morbidity, allowing for the administration of trimodality regimens in most patients. eP/D offered in a multimodality treatment setting have satisfactory long term oncological results. To obtain best oncological results the goal of surgery should be macroscopic complete resection in carefully selected patients (clinical N0).
DOI: 10.5519/qd.64o3vuye
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (4632 records)
DOI: 10.5281/zenodo.5997059
title: Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry

description: Dataset from Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, Hagl C, Borger MA, Taramasso M, Nguyen TC, Ailawadi G, Shah AS, Smith RL, Anselmi A, Romano MA, Ben Ali W, Ramlawi B, Grubb KJ, Robinson NB, Pirelli L, Chu MWA, Andreas M, Obadia JF, Gennari M, Garatti A, Tchetche D, Nazif TM, Bapat VN, Modine T, Denti P, Tang GHL; CUTTING-EDGE Investigators. Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2010-2021. doi: 10.1016/j.jcin.2021.07.029. PMID: 34556275. Abstract <strong>Objectives: </strong>The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER). <strong>Background: </strong>Although &gt;100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking. <strong>Methods: </strong>Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year. <strong>Results: </strong>From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery. <strong>Conclusions: </strong>In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only &lt;10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.
DOI: 10.5281/zenodo.5997058
title: Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry

description: Dataset from Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, Hagl C, Borger MA, Taramasso M, Nguyen TC, Ailawadi G, Shah AS, Smith RL, Anselmi A, Romano MA, Ben Ali W, Ramlawi B, Grubb KJ, Robinson NB, Pirelli L, Chu MWA, Andreas M, Obadia JF, Gennari M, Garatti A, Tchetche D, Nazif TM, Bapat VN, Modine T, Denti P, Tang GHL; CUTTING-EDGE Investigators. Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2010-2021. doi: 10.1016/j.jcin.2021.07.029. PMID: 34556275. Abstract <strong>Objectives: </strong>The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER). <strong>Background: </strong>Although &gt;100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking. <strong>Methods: </strong>Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year. <strong>Results: </strong>From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery. <strong>Conclusions: </strong>In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only &lt;10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.
DOI: 10.5517/ccdc.csd.cc1zv0vp
title: CSD 1842263: Experimental Crystal Structure Determination

description: Related Article: Alessia Provino, Volodymyr Smetana, Timothy A. Hackett, Durga Paudyal, Manish K. Kashyap, Cristina Bernini, Amitava Bhattacharyya, Sudesh K. Dhar, Marcella Pani, Flavio Gatti, Anja-Verena Mudring, Pietro Manfrinetti|2019|Inorg.Chem.|58|15045|doi:10.1021/acs.inorgchem.9b01440
DOI: 10.5517/ccdc.csd.cc1zv0wq
title: CSD 1842264: Experimental Crystal Structure Determination

description: Related Article: Alessia Provino, Volodymyr Smetana, Timothy A. Hackett, Durga Paudyal, Manish K. Kashyap, Cristina Bernini, Amitava Bhattacharyya, Sudesh K. Dhar, Marcella Pani, Flavio Gatti, Anja-Verena Mudring, Pietro Manfrinetti|2019|Inorg.Chem.|58|15045|doi:10.1021/acs.inorgchem.9b01440
DOI: 10.5517/ccdc.csd.cc1zv0xr
title: CSD 1842265: Experimental Crystal Structure Determination

description: Related Article: Alessia Provino, Volodymyr Smetana, Timothy A. Hackett, Durga Paudyal, Manish K. Kashyap, Cristina Bernini, Amitava Bhattacharyya, Sudesh K. Dhar, Marcella Pani, Flavio Gatti, Anja-Verena Mudring, Pietro Manfrinetti|2019|Inorg.Chem.|58|15045|doi:10.1021/acs.inorgchem.9b01440
DOI: 10.5517/ccdc.csd.cc1zv0ys
title: CSD 1842266: Experimental Crystal Structure Determination

description: Related Article: Alessia Provino, Volodymyr Smetana, Timothy A. Hackett, Durga Paudyal, Manish K. Kashyap, Cristina Bernini, Amitava Bhattacharyya, Sudesh K. Dhar, Marcella Pani, Flavio Gatti, Anja-Verena Mudring, Pietro Manfrinetti|2019|Inorg.Chem.|58|15045|doi:10.1021/acs.inorgchem.9b01440